Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07232199

Clinical Investigation of Sensovisc Sterile Sodium Hyaluronate Gel

This clinical investigation aims to investigate the safety and performance of Sensovisc.Sensovisc is used to reduce osteoarthritis related pain in the joints by supporting synovial fluid by intra-articular injection and allowing the synovial fluid to restore its viscoelastic properties. It increases the joint mobility by reducing or eliminating the pain.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis, Hip Rheumatic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Osteoarthritis (OA) is the most prevalent chronic arthritis and a leading cause of pain and disability among adults. OA is a degenerative joint disease characterized by chronic inflammation, cartilage degradation and erosion of underlying bone in the affected joints, predominantly affects knees, significantly impacting patient mobility and quality of life. • Although there are currently no approved disease-modifying OA drugs (DMOADs), nonpharmacologic interventions, such as physical therapy and weight management, and pharmaceutical approaches are available to reduce or revise joint damage and inflammation.• Among various therapeutic interventions, intra-articular hyaluronic acid (HA) injections have emerged as an alternative promising treatment. Emerging evidence suggests that HA may exert chondroprotective effects by enhancing synovial fluid viscosity, improving joint lubrication, and mitigating inflammatory processes, thereby potentially decelerating disease progression and preserving cartilage integrity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >18 years old
  • Patients who have unilateral and/or bilateral hip pain for more than 3 months and meet the diagnosis of coxarthrosis according to ACR criteria
  • 40 mm above the pain level determined by the Visual Analogue Scale (VAS) during rest for at least 15 days in the month before starting the study (for paracetamol and oral NSAIDs, taking into account the half-life of the drug).
  • Diagnosis of hip osteoarthritis with Stage II or III according to the Kellgren and Lawrence (KL) classification, as determined by x-rays taken in the last 12 months
  • Ambulating with or without support
  • Having the mental ability to express pain scores
  • Signing the informed consent form indicating consent to participate in the study

Exclusion criteria

  • Radiological Kellgren-Lawrence (K&L) stage I or IV
  • Other non-degenerative causes of hip pain
  • septic arthritis
  • Avascular necrosis,
  • Femoroacetabular impingement syndrome,
  • Trochanteric bursitis
  • Having a history of lower extremity fracture/surgery within the last 6 months
  • Pregnancy, breastfeeding, pregnancy plan
  • Morbidly obese patients (BMI>40),
  • Patients with unstable medical conditions (liver or kidney failure, lung/heart disease, tumor, HIV, etc.)
  • Known central nervous system and/or peripheral nervous system disease
  • When fluoroscopy guided injection is contraindicated:
  • pregnancy,
  • contrast material allergy,
  • local anesthetic allergy,
  • Having conditions such as coagulopathy
  • Related to Treatment
  • Corticosteroid injection into the target joint within the last 1 month before the first injection
  • Hyaluronan injection into the target joint within the last 6 months before the first injection
  • Arthroscopy or surgery on the target joint within the last 6 months before the first injection
  • Those who use blood thinners (warfarin compounds and heparin) or have bleeding problems
  • Contraindications for SENSOVISC: Hypersensitivity to product ingredients, systemic infection, presence of local infection on the buttocks, infection or skin disease at the injection site or joint area

Treatment and study plan

SV-3-75: Sterile Sodium Hyaluronate Gel-3 mL Prefilled Syringe (2.5%)

Device

Sensovisc is used to reduce osteoarthritis related pain in the joints by supporting synovial fluid by intra-articular injection and allowing the synovial fluid to restore its viscoelastic properties. It increases the joint mobility by reducing or eliminating the pain. It will be injected in hip joint in this investigation. The injection will be administered under fluoroscopic and ultrasound guidance.

Primary outcomes

  1. Visual Analogue Scale (VAS)

    Time frame: Baseline

    VAS at rest: Measures pain intensity while resting. Scale 0-10 cm (0 = no pain, 10 = worst imaginable pain). Higher scores = worse pain at rest.

    VAS at night: Measures pain intensity during the night, especially disturbing sleep. Scale 0-10 cm. Higher scores = worse nocturnal pain.

    VAS during activity: Measures pain intensity during movement or activity. Scale 0-10 cm. Higher scores = worse pain on activity.

  2. Change in Visual Analogue Scale (VAS) score from baseline at 6 weeks

    Time frame: 6 weeks after the injection

    VAS at rest: Measures pain intensity while resting. Scale 0-10 cm (0 = no pain, 10 = worst imaginable pain). Higher scores = worse pain at rest.

    VAS at night: Measures pain intensity during the night, especially disturbing sleep. Scale 0-10 cm. Higher scores = worse nocturnal pain.

    VAS during activity: Measures pain intensity during movement or activity. Scale 0-10 cm. Higher scores = worse pain on activity.

  3. Change in Visual Analogue Scale (VAS) score from baseline at 6 months

    Time frame: 6 months after the injection

    VAS at rest: Measures pain intensity while resting. Scale 0-10 cm (0 = no pain, 10 = worst imaginable pain). Higher scores = worse pain at rest.

    VAS at night: Measures pain intensity during the night, especially disturbing sleep. Scale 0-10 cm. Higher scores = worse nocturnal pain.

    VAS during activity: Measures pain intensity during movement or activity. Scale 0-10 cm. Higher scores = worse pain on activity.

  4. WOMAC Osteoarthritis Index

    Time frame: Baseline

    The WOMAC Index is a self-administered questionnaire designed to evaluate symptoms and functional limitations in hip and knee osteoarthritis. It has 3 subscales:

    Pain (0-20) Stiffness (0-8) Physical function (0-68) The total score ranges from 0 to 96, with higher scores indicating worse pain, stiffness, and functional impairment.

  5. Change in WOMAC Osteoarthritis Score from baseline at 6 weeks

    Time frame: 6 weeks after the injection

    The WOMAC Index is a self-administered questionnaire designed to evaluate symptoms and functional limitations in hip and knee osteoarthritis. It has 3 subscales:

    Pain (0-20) Stiffness (0-8) Physical function (0-68) The total score ranges from 0 to 96, with higher scores indicating worse pain, stiffness, and functional impairment.

  6. Change in WOMAC Osteoarthritis Score from baseline at 6 months

    Time frame: 6 months after the injection

    The WOMAC Index is a self-administered questionnaire designed to evaluate symptoms and functional limitations in hip and knee osteoarthritis. It has 3 subscales:

    Pain (0-20) Stiffness (0-8) Physical function (0-68) The total score ranges from 0 to 96, with higher scores indicating worse pain, stiffness, and functional impairment.

  7. Harris Hip Score (HHS)

    Time frame: Baseline

    It is a clinician-administered tool used to assess hip pain, function, deformity, and range of motion, with a total score ranging from 0 to 100 (higher scores indicate better function). Scores are categorized as excellent (90-100), good (80-89), fair (70-79), and poor (<70). The HHS will be used to evaluate hip function before and after the intervention.

  8. Change in Harris Hip Score (HHS) from baseline at 6 weeks

    Time frame: 6 weeks after last injection

    It is a clinician-administered tool used to assess hip pain, function, deformity, and range of motion, with a total score ranging from 0 to 100 (higher scores indicate better function). Scores are categorized as excellent (90-100), good (80-89), fair (70-79), and poor (<70). The HHS will be used to evaluate hip function before and after the intervention.

  9. Change in Harris Hip Score (HHS) from baseline at 6 weeks

    Time frame: 6 months after last injection

    It is a clinician-administered tool used to assess hip pain, function, deformity, and range of motion, with a total score ranging from 0 to 100 (higher scores indicate better function). Scores are categorized as excellent (90-100), good (80-89), fair (70-79), and poor (<70). The HHS will be used to evaluate hip function before and after the intervention.

Study contacts

Contact information is provided by the study sponsor or research team.

Hayriye Şimşek Özgüner

CONTACT

[email protected]

+90 5543814289

Sponsors and collaborators

Lead sponsor

Ankara City Hospital Bilkent

Other

Collaborators

  • İstem Medikal Tıbbi Cihaz ve Sanayi Ticaret Anonim Şirketi

Registry information

Official study title

Clinical Investigation of Sensovisc Sterile Sodium Hyaluronate Gel in the Hip Joint

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 18, 2025
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.